Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.
Coomans MB, Dirven L, Aaronson N, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB. Coomans MB, et al. Among authors: malmstrom a. Neuro Oncol. 2022 Dec 1;24(12):2159-2169. doi: 10.1093/neuonc/noac097. Neuro Oncol. 2022. PMID: 35404443 Free PMC article.
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG). Malmström A, et al. Lancet Oncol. 2012 Sep;13(9):916-26. doi: 10.1016/S1470-2045(12)70265-6. Epub 2012 Aug 8. Lancet Oncol. 2012. PMID: 22877848 Clinical Trial.
The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials.
Coomans M, Dirven L, K Aaronson N, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB; EORTC Quality of Life Group and the EORTC Brain Tumor Group. Coomans M, et al. Among authors: malmstrom a. Eur J Cancer. 2019 Jul;116:190-198. doi: 10.1016/j.ejca.2019.05.012. Epub 2019 Jun 13. Eur J Cancer. 2019. PMID: 31203194 Free article.
Glioblastoma in the elderly: making sense of the evidence.
Mason M, Laperriere N, Wick W, Reardon DA, Malmstrom A, Hovey E, Weller M, Perry JR. Mason M, et al. Among authors: malmstrom a. Neurooncol Pract. 2016 Jun;3(2):77-86. doi: 10.1093/nop/npv027. Epub 2015 Sep 1. Neurooncol Pract. 2016. PMID: 31386084 Free PMC article.
Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
Coomans MB, Dirven L, Aaronson NK, Baumert BG, Van Den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB. Coomans MB, et al. Among authors: malmstrom a. Neuro Oncol. 2019 Nov 4;21(11):1447-1457. doi: 10.1093/neuonc/noz118. Neuro Oncol. 2019. PMID: 31682733 Free PMC article.
Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients.
Coomans MB, Taphoorn MJB, Aaronson NK, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Dirven L. Coomans MB, et al. Among authors: malmstrom a. Neurooncol Pract. 2020 Jun 7;7(6):668-675. doi: 10.1093/nop/npaa033. eCollection 2020 Dec. Neurooncol Pract. 2020. PMID: 33304601 Free PMC article.
Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling.
Coomans MB, Dirven L, Aaronson NK, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Sloan JA, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB. Coomans MB, et al. Among authors: malmstrom a. Neurooncol Adv. 2020 Oct 29;2(1):vdaa147. doi: 10.1093/noajnl/vdaa147. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33409496 Free PMC article.
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.
Bady P, Marosi C, Weller M, Grønberg BH, Schultz H, Taphoorn MJB, Gijtenbeek JMM, van den Bent MJ, von Deimling A, Stupp R, Malmström A, Hegi ME. Bady P, et al. Among authors: malmstrom a. Acta Neuropathol Commun. 2022 Mar 24;10(1):39. doi: 10.1186/s40478-022-01344-5. Acta Neuropathol Commun. 2022. PMID: 35331339 Free PMC article.
191 results